Royalty Pharma Acquires $310M Royalty Interest in Alnylam's AMVUTTRA

Royalty Pharma has acquired a royalty interest in Alnylam's AMVUTTRA, an FDA-approved RNAi therapeutic for ATTR amyloidosis, from Blackstone Life Sciences for $310 million. The acquisition stems from Blackstone's 2020 financing collaboration with Alnylam to support the drug's Phase 3 trial. AMVUTTRA delivers compelling benefits to patients, including a reduction in all-cause mortality for ATTR cardiomyopathy patients.